Pre-exposure prophylaxis, more commonly referred to as PrEP, is an anti-retroviral drug taken by HIV-negative people which, if used consistently, can help to dramatically reduce the risk of acquiring the virus.
PrEP was previously available in England as part of the Impact trial, but now the Government has given local councils funding to uncap its availability and make it more widely accessible.
This wider rollout was previously delayed due to the ongoing COVID-19 global pandemic, but is now expected to begin on 1 October. “With three working days before the start of October – the delayed but finally promised launch of uncapped PrEP access in England – the Health Department has finally allocated funds to local government to start the roll